Platinum Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Platinum Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,001	Closed	-$999K	–	133
2024 Q3	$999K	Sell	8,001 -3,300	-29%	-$456K	0.05%	82
2024 Q2	$1.79M	Buy	11,301 +1,026	+10%	+$132K	0.07%	68
2024 Q1	$1.33M	Hold	10,275	–	–	0.05%	82
2023 Q4	$991K	Hold	10,275	–	–	0.04%	92
2023 Q3	$1.25M	Buy	10,275 +241	+2%	+$27.2K	0.05%	88
2023 Q2	$1.15M	Hold	10,034	–	–	0.04%	94
2023 Q1	$1.38M	Sell	10,034 -4,214	-30%	-$547K	0.05%	93
2022 Q4	$1.85M	Buy	+14,248	New	+$1.65M	0.07%	81

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Platinum Investment Management's SRPT Position: Q4 2024 in Review

Platinum Investment Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 8,001 shares — an estimated $999K sold.

Platinum Investment Management first reported a position in SRPT in Q4 2022 and held it in 8 quarters. The position peaked at $1.85M in Q4 2022. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Platinum Investment Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Platinum Investment Management sold 8,001 Sarepta Therapeutics shares in Q4 2024, an estimated $999K.
Platinum Investment Management first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 8 quarters.
Platinum Investment Management's Sarepta Therapeutics position peaked at $1.85M in Q4 2022.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Platinum Investment Management's 13F filing for Q4 2024, filed 11 Feb 2025.